DSM Capital Partners LLC Decreases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

DSM Capital Partners LLC lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 932,595 shares of the company's stock after selling 11,559 shares during the quarter. Neurocrine Biosciences comprises 2.0% of DSM Capital Partners LLC's investment portfolio, making the stock its 17th biggest holding. DSM Capital Partners LLC owned about 0.92% of Neurocrine Biosciences worth $127,299,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently made changes to their positions in the company. Golden State Wealth Management LLC bought a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $25,000. Brooklyn Investment Group lifted its position in Neurocrine Biosciences by 99.1% in the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company's stock valued at $32,000 after acquiring an additional 115 shares in the last quarter. Blue Trust Inc. lifted its position in Neurocrine Biosciences by 171.9% in the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company's stock valued at $40,000 after acquiring an additional 220 shares in the last quarter. R Squared Ltd bought a new position in Neurocrine Biosciences in the 4th quarter valued at about $61,000. Finally, UMB Bank n.a. lifted its position in Neurocrine Biosciences by 211.6% in the 4th quarter. UMB Bank n.a. now owns 455 shares of the company's stock valued at $62,000 after acquiring an additional 309 shares in the last quarter. Institutional investors own 92.59% of the company's stock.

Insider Transactions at Neurocrine Biosciences

In other Neurocrine Biosciences news, Director Kevin Charles Gorman sold 146,105 shares of the business's stock in a transaction on Monday, January 27th. The shares were sold at an average price of $149.46, for a total value of $21,836,853.30. Following the completion of the sale, the director now directly owns 514,596 shares of the company's stock, valued at $76,911,518.16. The trade was a 22.11 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Matt Abernethy sold 1,283 shares of the business's stock in a transaction on Friday, January 31st. The stock was sold at an average price of $152.87, for a total transaction of $196,132.21. Following the completion of the sale, the chief financial officer now directly owns 32,681 shares of the company's stock, valued at $4,995,944.47. This represents a 3.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 236,600 shares of company stock valued at $34,348,261. Insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on NBIX shares. Wedbush dropped their price target on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an "outperform" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada dropped their price target on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a "sector perform" rating on the stock in a research report on Friday, February 7th. Guggenheim decreased their price objective on shares of Neurocrine Biosciences from $165.00 to $163.00 and set a "buy" rating for the company in a research note on Monday, February 10th. Piper Sandler reiterated an "overweight" rating and issued a $160.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 23rd. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Neurocrine Biosciences in a research note on Tuesday, February 11th. They issued a "hold" rating and a $138.00 price objective for the company. Five research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $166.90.

Neurocrine Biosciences Stock Up 3.9 %

Shares of NASDAQ NBIX traded up $4.58 during mid-day trading on Friday, reaching $120.69. 1,960,426 shares of the company were exchanged, compared to its average volume of 1,340,165. Neurocrine Biosciences, Inc. has a 52 week low of $110.95 and a 52 week high of $157.98. The stock has a market capitalization of $12.03 billion, a PE ratio of 36.68, a PEG ratio of 0.76 and a beta of 0.33. The company's 50 day moving average price is $136.75 and its 200 day moving average price is $129.71.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. On average, sell-side analysts predict that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current year.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.